|
|
Vol. 27.09 – 25 May, 2026
|
|
|
|
|
|
|
|
|
Using syngeneic models of extensive metastatic lung adenocarcinoma and melanoma, investigators showed that 8 Gy of tumor irradiation significantly enhanced CAR T cell persistence in a manner critically dependent on dendritic cells. [Nature Cancer]
|
|
|
|
|
|
PUBLICATIONSListed by the impact factor of the journal
|
|
|
|
|
|
Scientists generated urokinase plasminogen activator receptor (uPAR)-specific CAR T cells, which demonstrated potent antitumor activity in recurrent glioblastoma patient–derived xenograft models.
[Science Translational Medicine]
|
|
|
|
|
|
Through head-to-head in vivo comparisons of potentially synergistic armor combinations, researchers demonstrated that T cells expressing a CAR plus IL-12 and the decoy-resistant form of IL-18 show strong efficacy against antigen-heterogeneous glioma in immunocompetent mice.
[Cancer Research]
|
|
|
|
|
|
Researchers engineered iPSC-derived cytotoxic T cells transduced with a CAR and identified an optimal cytokine armoring strategy. Co-expression of interleukin (IL)-15 and IL-21 synergistically enhanceds STAT1 phosphorylation, leading to increased transcriptional activation of the chemokine receptor CXCR3.
[Molecular Therapy]
|
|
|
|
|
|
Scientists monitored anti-CAR therapeutic domain-specific antibodies (ATAs) in 157 treated patients to assess treatment-related immunogenicity. The ATA status did not affect CAR T-cell expansion or patient survival outcomes, though reduced persistence was observed in ATA-positive patients.
[Molecular Therapy]
|
|
|
|
|
|
In this first-in-human open-label study, autologous FLT3 CAR-T cells were delivered to two patients with relapsed and refractory FLT3+ acute myeloid leukemia. [NPJ Precision Oncology]
|
|
|
|
|
|
|
|
CAR-expressing cells—initially developed and successfully used to treat certain cancers—are increasingly being developed to selectively deplete B cells and ‘reset’ the immune system in autoimmune diseases.
[Nature Medicine]
|
|
|
|
|
|
The emergence of in vivo CAR-T therapy medicinal products using viral vector or lipid nanoparticle platforms has provided a promising new direction by simplifying manufacturing, enhancing scalability, and lowering costs, though it may introduce elevated risks such as off-target effects and immunogenicity.
[Signal Transduction and Targeted Therapy]
|
|
|
|
|
|
This review synthesizes recent advances in CAR-T cell bioengineering aimed at overcoming physical barriers, immunosuppressive signaling, metabolic stress, and cellular exhaustion that characterize solid tumors, which are a leading cause of cancer-related mortality worldwide. [Trends in Biotechnology]
|
|
|
|
|
|
|
|
Dr. Siddhartha Mitra recently received a three-year grant to develop CAR macrophages therapies to treat diffuse midline gliomas, a particularly deadly type of pediatric brain cancer.
[University of Colorado Anschutz Cancer Center]
|
|
|
|
|
|
CellChorus, Inc. announced that the National Cancer Institute has awarded CellChorus® and Stanford Medicine a grant to profile cells from relapsed/refractory large B cell lymphoma patients after treatment with CAR-T cell therapy to develop a functional signature of response to therapy. [CellChorus, Inc.]
|
|
|
|
|
|
|
|
June 22-23, 2026 New York City, New York, United States
|
|
|
|
|
|
|
|
|
|
|
St Jude Children’s Research Hospital – Memphis, Tennessee, United States
|
|
|
|
|
|
|
Paul-Ehrlich-Institut – Langen, Germany
|
|
|
|
|
|
|
Dana Farber Cancer Institute – Boston, Massachusetts, United States
|
|
|
|
|
|
|
Dana-Farber Cancer Institute – Boston, Massachusetts, United States
|
|
|
|
|
|
|
Fred Hutchinson Cancer Center – Seattle, Washington, United States
|
|
|
|
|
|